AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03765125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: collagen peptide test
Description: Collagen peptides from bovine skin with an average molecular weight of approx. 2,000 g/mol. Average particle size is about 150 μm.
Study NCT03765125 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: collagen peptide placebo
Description: collagen peptide placebo
Study NCT04419467 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL346
Description: VEGF-B antagonist monoclonal antibody
Study NCT04419467 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT02563145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI feedback
Description: feedback about activation patterns in brain regions related with instrumental aggression
Study NCT02563145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Psychoeducation, general counselling
Study NCT02448966 — intervention group
Intervention type: PROCEDURE
Intervention: open esophagectomy
Study NCT02557854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin HCl liposomal injection
Description: 50mg IV every 4 weeks
Study NCT02557854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Philips Sonalleve MR-HIFU Hyperthermia
Description: Hyperthermia to 42C for 30 minutes every 4 weeks
Study NCT02733406 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Target Controlled Infusion
Study NCT02733406 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Velocity Controlled Infusion
Study NCT01396902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
Study NCT01396902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
Study NCT01151540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rufinamide
Description: The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
Study NCT02448966 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive esophagectomy
Study NCT01344798 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV1-gamma-sarcoglycan vector injection
Description: single intramuscular injection into carpi radialis muscle under open procedure
Study NCT02905903 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tricholoacetic Acid (TCA)
Description: We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
Study NCT01176370 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Pulse™ (Implantable Counterpulsation Therapy)
Description: C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device.
Study NCT04413721 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfustion
Description: When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
Study NCT04413721 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RBC transfustion
Description: When the hemoglobin concentration fell below 7.0 g per deciliter, RBC were given to maintain the hemoglobin concentrations in the range of 7.0 to 10.0g /dL
Study NCT02982486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1 mg/kg every 6 weeks
Study NCT02982486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Ninolumab 240 mg IV every 2 weeks
Study NCT02705118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic Imaging fusion of ultrasonography and MRI
Description: Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
Study NCT02705118 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Imaging fusion of ultrasonography and MRI
Description: Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
Study NCT00649441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Description: 20/25mg, single dose fasting
Study NCT00649441 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Accuretic™ Tablets 20 mg/25 mg
Description: 20/25mg, single dose fasting
Study NCT03786198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activity program
Description: Home-based walking intervention, wearing a wrist worn activity tracker, for 24 weeks
Study NCT03786198 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Physical activity according to standard recommendations, wearing a wrist worn activity tracker (with no feedback about performed activity), for 24 weeks + standard adjuvant AI therapy
Study NCT04157868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhBNP
Description: rhBNP intra-coronary injection 1.5 ug/kg loading dose, with intravenous injection 0.0075-0.01 ug/kg/min persistent for 72 hour.
Study NCT04157868 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Saline intra-coronary injection 0.15ml/kg loading dose, with same intravenous injection speed for 72 hour.
Study NCT01131897 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study NCT01131897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
Study NCT02527395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief thermal sensitization
Description: A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
Study NCT02527395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain during 1 min. thermal stimulation
Description: A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
Study NCT02987816 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
Study NCT02987816 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
Study NCT03305536 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K2 (Menaquinone 7) + Vitamin D3
Description: Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
Study NCT02380105 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
Study NCT02380105 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interocclusal Appliances
Description: Patients were treated using interocclusal appliances
Study NCT03072316 — intervention group
Intervention type: OTHER
Intervention: 3D surface imaging
Description: 3D photography
Study NCT03072316 — intervention group
Intervention type: OTHER
Intervention: semi-structured interview
Description: qualitative analysis using semi structured interview
Study NCT03831815 — intervention group
Intervention type: DRUG
Intervention: Cisatracurium
Description: Patients were allocated to two groups based on the neuromuscular blocker used by the anesthesiologist participating in the surgery. In group C, the patients in whom cisatracurium was given and the R group consisted of the patients in whom rocuronium was administered. It is emphasized that the choice of the neuromuscular blocker was made by the preference and experience of the anesthesiologist of the case and not by randomization or lottery of the patients.
Study NCT00735670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine HCl
Description: Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
Study NCT00735670 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
Study NCT00799929 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: in vitro fertilization (IVF/ICSI)
Study NCT02527395 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Heat pain detection threshold
Description: The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
Study NCT03072316 — intervention group
Intervention type: OTHER
Intervention: applanation tonometry
Description: measurement of breast compressibility
Study NCT01109498 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
Study NCT01109498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: oral, 2 g/day, day -3 till week 12
Study NCT01109498 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]
Description: intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
Study NCT03250494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulox capsule (60mg)
Description: each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
Study NCT03250494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI
Description: each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
Study NCT03250494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone
Description: each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
Study NCT04014855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: in iron deficiency anemia
Study NCT02302664 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRP Injection into Achilles tendon rupture gap
Description: PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
Study NCT02302664 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Imitation Injection into Achilles tendon rupture gap
Description: Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
Study NCT02351544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin Type A
Study NCT02351544 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Study NCT02351544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Daily headache diary
Study NCT02351544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine Disability Assessment Test (MIDAS)
Study NCT03928353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Description: Ticagrelor 180 mg + 90 mg BID for 5 doses prior to PB2452 or Placebo and Ticagrelor 180 mg 24 hours following PB2452 or Placebo
Study NCT03928353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor Oral Tablet - Pre-Treatment
Description: Ticagrelor 180 mg BID for 5 doses prior to PB2452 or Placebo
Study NCT01109498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: oral, 3 mg/kg/day, day -3 till week 12
Study NCT03928353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PB2452 Infusion
Description: 30 minute - 16 hour infusion
Study NCT03965182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG
Description: 2 sachets of PEG will be used as the bowel prep regimen.
Study NCT03965182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PEG plus SPMC
Description: one sachet of PEG and one sachet will be administered as the bowel prep regimen
Study NCT03965182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPMC
Description: 2 sachets will be administered as the bowel prep regimen.
Study NCT03483454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise class
Description: Same as above.
Study NCT04084249 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA-analysis
Description: Minimally-invasive blood-based analysis of circulating tumor DNA (ctDNA).
Study NCT04084249 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensified Follow-up Schedule
Description: PET/CT-scans every 3. month
Study NCT01355549 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy
Description: Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
Study NCT02097394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combizym
Description: Combizym( 1 tablet, po, tid)
Study NCT02097394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacteri
Description: Bifidobacteri (2 tablet, po, tid)
Study NCT02097394 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combizym + Bifidobacteri
Description: Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
Study NCT03483454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home exercise
Description: Same as above.
Study NCT01111162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H1N1 vaccination
Description: Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
Study NCT03050957 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: menthol
Description: Alimentary bolus supplemented with menthol
Study NCT02351544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine Work and Productivity Loss Questionnaire (MWPLQ)
Study NCT02351544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Migraine-Specific Quality of Life Questionnaire (MSQ)
Study NCT02593435 — intervention group
Intervention type: GENETIC
Intervention: NGS test
Description: To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.~To know mutation characteristic spectrum of BRCA1/2.
Study NCT04560348 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adventure-based cognitive behavioral intervention
Description: The adventure-based cognitive behavioral intervention is a combination of cognitive behavioral therapy and adventure training. The intervention program is delivered in a 39-hour general education course in a public university in Hong Kong. The program includes 6 lectures, 5 workshops, 5 adventure games and an adventure day camp. Students are divided into two groups in workshop to practise CBT skills to deal with their own issues.
Study NCT03274674 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: I-PRF
Description: Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
Study NCT03274674 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: I-PRF
Description: Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
Study NCT04499365 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-DOTA/NOTA-FAPI-04
Description: Each patient receive a single intravenous injection of 68Ga-DOTA/NOTA-FAPI-04, and undergo PET/CT scan within specified time.
Study NCT04499365 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: PET/CT scan
Study NCT03673319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling with positives expectation
Description: DN procedure: is a very effective form of treatment used to treat neck-shoulder pain and it is expected to reduce your perception of pressure pain
Study NCT03673319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dry needling with neutral expectation
Description: DN procedure: is a form of treatment used to treat neck-shoulder pain that has unknown effects on your perception of pressure pain
Study NCT02109536 — intervention group
Intervention type: DEVICE
Intervention: Magnetic endoscopic imager.
Description: recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
Study NCT02304458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV
Study NCT02304458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02304458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT02304458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02198326 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBN 4096 BS- in single rising doses
Study NCT02198326 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01108666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.